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Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic
efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse
that inhibits neurotransmitter release upon activating presynaptic CB1 cannabinoid receptors. Cognitive decline in Alzheimer’s
disease is due to synaptic failure in hippocampal neuronal networks. We hypothesized that errant retrograde 2-arachidonoyl
glycerol signalling impairs synaptic neurotransmission in Alzheimer’s disease. Comparative protein profiling and quantitative
morphometry showed that overall CB1 cannabinoid receptor protein levels in the hippocampi of patients with Alzheimer’s
disease remain unchanged relative to age-matched controls, and CB1 cannabinoid receptor-positive presynapses engulf
amyloid-b-containing senile plaques. Hippocampal protein concentrations for the sn-1-diacylglycerol lipase a and b isoforms,
synthesizing 2-arachidonoyl glycerol, significantly increased in definite Alzheimer’s (Braak stage VI), with ectopic sn-
1-diacylglycerol lipase b expression found in microglia accumulating near senile plaques and apposing CB1 cannabinoid
receptor-positive presynapses. We found that microglia, expressing two 2-arachidonoyl glycerol-degrading enzymes, serine
hydrolase a/b-hydrolase domain-containing 6 and monoacylglycerol lipase, begin to surround senile plaques in probable
Alzheimer’s disease (Braak stage III). However, Alzheimer’s pathology differentially impacts serine hydrolase a/b-hydrolase
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domain-containing 6 and monoacylglycerol lipase in hippocampal neurons: serine hydrolase a/b-hydrolase domain-containing 6
expression ceases in neurofibrillary tangle-bearing pyramidal cells. In contrast, pyramidal cells containing hyperphosphorylated
tau retain monoacylglycerol lipase expression, although at levels significantly lower than in neurons lacking neurofibrillary
pathology. Here, monoacylglycerol lipase accumulates in CB1 cannabinoid receptor-positive presynapses. Subcellular fraction-
ation revealed impaired monoacylglycerol lipase recruitment to biological membranes in post-mortem Alzheimer’s tissues,
suggesting that disease progression slows the termination of 2-arachidonoyl glycerol signalling. We have experimentally con-
firmed that altered 2-arachidonoyl glycerol signalling could contribute to synapse silencing in Alzheimer’s disease by demon-
strating significantly prolonged depolarization-induced suppression of inhibition when superfusing mouse hippocampi with
amyloid-b. We propose that the temporal dynamics and cellular specificity of molecular rearrangements impairing
2-arachidonoyl glycerol availability and actions may differ from those of anandamide. Thus, enhanced endocannabinoid signal-
ling, particularly around senile plaques, can exacerbate synaptic failure in Alzheimer’s disease.
Keywords: glia; human; neurodegeneration; retrograde signalling; synapse
Abbreviations: ABHD6 = serine hydrolase a/b-hydrolase domain-containing 6; DAGL = sn-1-diacylglycerol lipase;
FAAH = fatty-acid amide hydrolase; IBA-1 = ionized Ca2 + -binding adaptor molecule-1; MAP2 = microtubule-associated protein 2;
NAPE-PLD = N-acyl phosphatidylethanolamide-specific phospholipase D; PSD95 = postsynaptic density protein of 95 kDa;
SNAP25 = synaptosomal-associated protein of 25 kDa; TRPV1 = transient receptor potential cation channel subfamily
V member 1
Introduction
Alzheimer’s disease is the most common form of age-related de-
mentia. Although two competing hypotheses exist as to the mo-
lecular sequel behind neuronal demise in Alzheimer’s disease
(Small and Duff, 2008), the ultimate and invariable outcome of
both intracellular tau hyperphosphorylation, and overt production
and extracellular release of amyloid-b is impaired synaptic com-
munication, particularly in the hippocampus (Oddo et al., 2003;
Walsh and Selkoe, 2004). Oligomeric amyloid-b can target exci-
tatory synapses (Shemer et al., 2006), where amyloid-b disrupts
the molecular machinery underpinning both presynaptic neuro-
transmitter release and postsynaptic responsiveness, thus impairing
various forms of short- and long-term synaptic plasticity
(Walsh et al., 2002; Shemer et al., 2006). A causal relationship
between amyloid-b-induced NMDA and AMPA receptor removal
and dephosphorylation (Kamenetz et al., 2003; Snyder et al.,
2005; Hsieh et al., 2006; Gu et al., 2009) and impaired intracel-
lular Ca2+ signalling in the postsynapse (Kuchibhotla et al., 2008),
predominantly in dendritic spines receiving excitatory inputs, has been
identified as a determinant of amyloid-b-induced synaptic
dysfunction.
The temporal dynamics of neurotransmitter release at both ex-
citatory and inhibitory synapses are controlled by retrograde sig-
nalling networks (Alger, 2002), with retrograde messengers
liberated from the subsynaptic dendrite in temporal cohesion
with postsynaptic spike timing (Kano et al., 2009).
Endocannabinoid signalling is one such mechanism widely distrib-
uted in rodent (Katona et al., 2006), primate (Harkany et al.,
2005) and human brains (Ludanyi et al., 2011). Transgenic ana-
lyses (Gao et al., 2010; Tanimura et al., 2010) reveal that
2-arachidonoyl glycerol is a particularly efficacious endocannabi-
noid to tune synaptic communication in the hippocampus. The
canonical pathway of 2-arachidonoyl glycerol metabolism posits
2-arachidonoyl glycerol synthesis by Ca2 +-dependent
sn-1-diacylglycerol lipases a and b (DAGLs) (Bisogno et al.,
2003), with DAGLs anchored at the neck of dendritic spines
(Uchigashima et al., 2007). Once released, 2-arachidonoyl glycerol
engages CB1 cannabinoid receptors at glutamatergic as well as
GABAergic presynapses (Kano et al., 2009). Monoacylglycerol
lipase (Dinh et al., 2002) and the serine hydrolase a/b-hydrolase
domain-containing 6 (ABHD6) are recruited to pre- (Hashimotodani
et al., 2007) and postsynaptic sites (Marrs et al., 2010), respect-
ively, to terminate 2-arachidonoyl glycerol signalling.
Age-related learning and memory deficits upon CB1 cannabinoid
receptor deletion (Bilkei-Gorzo et al., 2005) or phytocannabinoid
administration (Wise et al., 2009) illustrate the physiological sig-
nificance of endocannabinoid signalling in the ageing brain. In
Alzheimer’s disease, endocannabinoids may exert dual roles
(Bisogno and Di Marzo, 2008). Increased endocannabinoid avail-
ability appears beneficial in reducing pro-inflammatory microglia
transformation and activity through a CB2 cannabinoid receptor-
dependent mechanism (Ramirez et al., 2005; Halleskog et al.,
2011). Alternatively, CB1 cannabinoid receptor modulation can
gate amyloid-b neurotoxicity and protect against amyloid-
b-induced amnesia in hippocampal learning tasks (Mazzola
et al., 2003; Micale et al., 2010). While CB1 cannabinoid receptor
activation during ongoing neurodegeneration clearly improves
cognitive outcome by inhibiting neuronal apoptosis and gliosis,
CB1 cannabinoid receptor agonist administration during advanced
neurodegeneration could instead worsen amyloid-b-induced neur-
onal demise by inhibiting residual neuronal activity (van der Stelt
et al., 2006). Nevertheless, experimental evidence unequivocally
identifying the impact of amyloid-b on endocannabinoid-mediated
forms of hippocampal synaptic plasticity is lacking.
Modifications to CB1 cannabinoid receptor expression and sig-
nalling efficacy in Alzheimer’s disease are ambiguous (Westlake
et al., 1994; Lee et al., 2010). In addition, coordinated expression
and subcellular distribution of CB1 cannabinoid receptors, DAGLs,
ABHD6 and monoacylglycerol lipase, and their relationship to
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retrograde signalling in Alzheimer’s disease, remain essentially un-
explored. We hypothesized a functional relationship between er-
rant 2-arachidonoyl glycerol signalling and synaptic impairment in
Alzheimer’s disease: amyloid-b could impact Ca2 +-dependent
2-arachidonoyl glycerol synthesis and release, while cytoskeletal
damage might alter subcellular DAGL, monoacylglycerol lipase
and/or ABHD6 recruitment, thus disrupting the dynamics of
2-arachidonoyl glycerol signalling. Irrespective of the primary
pathogenic cascade, molecular reorganization of 2-arachidonoyl
glycerol signalling networks might be detrimental to maintain syn-
aptic responsiveness and plasticity. We have tested these hypoth-
eses by dissecting the molecular machinery of 2-arachidonoyl
glycerol signalling in post-mortem human brains with Alzheimer’s
pathology, in transgenic mouse models and upon acute amyloid-b
challenge to hippocampal neurons.
Materials and methods
Human tissues
Hippocampal tissue samples were obtained from patients with Alzheimer’s
disease and age-matched controls (without clinical signs of neuropsychi-
atric disease) at the London Neurodegenerative Diseases Brain Bank
(Supplementary Table 1). Neuropathological and histochemical exam-
ination, including classification of amyloid-b plaque burden
(Supplementary Fig. 1A), tau pathology (Supplementary Table 1)
and synaptic impairment (Supplementary Fig. 1B–E), was performed
as described (Supplementary Material). Tissue blocks or entire hippo-
campi were immersion fixed in 4% paraformaldehyde in 0.1M phos-
phate buffer (pH 7.4) for 48–72 h at 4C, followed by long-term
storage in 0.1 M phosphate buffer to which 0.1% NaN3 had been
added. Alternatively, native tissue blocks (2–3 cm3) of 1 cm thickness
from the other hemisphere were stored at 80C until processing for
biochemical analysis.
APdE9 mice
Male APPswe/PS1dE9 (APdE9) transgenic mice and littermate controls
aged 7 or 14 months were used (n = 26 animals in total; ethical docu-
mentation of in vivo studies can be found in online Supplementary
Material). APdE9 mice were generated by heterozygously co-
expressing mutant amyloid-precursor protein (KM593/594NL) and
an exon 9 deletion variant of presenilin 1, both associated with familial
Alzheimer’s disease (Jankowsky et al., 2004).
Immunohistochemistry and imaging
Multiple immunofluorescence histochemistry on human temporal lobe
sections containing the hippocampal formation was performed by
applying select combinations of primary antibodies (Supplementary
Fig. 2, Supplementary Table 2) according to standard protocols
(Harkany et al., 2003, 2005; Keimpema et al., 2010; Halleskog
et al., 2011). Single x–y plane or orthogonal z image stacks were
captured, after quenching tissue autofluorescence (Supplementary
Fig. 3), by laser-scanning microscopy (710LSM, Zeiss) as described in
the online Supplementary Material. Three dimensional reconstruction
and rendering of dendrite segments to specify the spatial relationships
of DAGLa/DAGLb or monoacylglycerol lipase immunoreactivities was
performed using the BioVis3D reconstruction package (Montevideo)
according to the specific imaging criteria (Supplementary Methods).
Acute brain slice preparation and
electrophysiology
Patch clamp recordings, differential interference contrast imaging and
stimulus protocols in hippocampal slices from postnatal 14- or 16-day-
old mouse brains were performed as described (Supplementary Methods).
Western blotting
Protein samples prepared from human or mouse hippocampi were ana-
lysed under denaturing conditions. Western blot analysis was under-
taken as described (Supplementary Methods) with primary antibodies
listed in Supplementary Table 2. Blots were scanned on a Lycor
Odyssey-IR imager and quantified with ImageJ1.32j.
WNT-3A stimulation and gene
expression profiling in microglia
Primary microglia were isolated from newborn mouse brains
(Halleskog et al., 2011). Cultures typically contained 495% microglia,
as validated by cytochemistry with Griffonia simplicifolia isolectin B4
(Sigma). Three independent harvests of primary microglia were seeded
in six-well plates and challenged 24 h after plating. Serum-deprived
microglia were treated with either 0.1% bovine serum albumin (ve-
hicle control) or 300 ng/ml recombinant WNT-3A for 6 h. RNA was
prepared and analysed on an Affimetrix Mouse Gene 1.0 ST Array
(Halleskog et al., 2011). Real-time quantitative polymerase chain re-
action analysis was performed as reported previously with custom-
designed primers (Keimpema et al., 2010). N13 microglia-like cells
(Halleskog et al., 2011) were exposed to fibrillar amyloid-b1–42 at
100 nM final concentration for 48 h.
2-Arachidonoyl glycerol degradation in
Alzheimer’s brains
Biochemical studies were conducted in an independent cohort of human
cortical samples (Supplementary Material). Neurohistopathological evalu-
ation and disease classification were as above. Frontal cortices were mech-
anically homogenized (10%) in Tris–HCl (20mM, pH 7.2) containing 0.32
M sucrose and protease inhibitors, and centrifuged to eliminate nuclei and
cellular debris (1000g, 10min, 4C). Supernatants were ultracentrifuged
(100 000g, 60 min, 4C) to obtain membrane and soluble fractions, both
presenting 2-arachidonoyl glycerol-degrading activity (Blankman et al.,
2007). Protein concentrations were determined by Bradford’s colori-
metric method (Bradford, 1976). The 2-arachidonoyl glycerol-
degrading activity was assessed by incubating sample fractions
(10 mg protein) in a solution containing Tris–HCl (10 mM, pH 7.2),
1 mM ethylenediaminetetraacetic acid, fatty acid-free bovine serum al-
bumin (1.25 mg/ml), [3H]2-arachidonoyl glycerol ([1,2,3-3H]glycerol,
25 mM, 40 Ci/mmol specific activity; New England Nuclear) in a final
volume of 200ml for 15 min at 37C. Identical conditions were used to
assess anandamide degrading activity using [3H]-anandamide
([1-3H]ethanolamine, 25 mM, 40 Ci/mmol specific activity; ARC Inc.).
Reactions were stopped by 400ml chloroform:methanol (2:1, v/v) and
vigorous vortexing. Fractions either containing [1,2,3-3H]glycerol/
[1-3H]ethanolamine (top) or non-hydrolyzed [3H]2-arachidonoyl
glycerol/[3H]anandamide (bottom/organic) were separated by
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centrifugation (2000 g, 10 min, 4C), transferred into scintillation vials
and radioactivity measured by liquid scintillation spectroscopy. Actual
experimental conditions were selected from pilot experiments assaying
the relationship of substrate and protein concentrations to identify
optimal 2-arachidonoyl glycerol-degrading enzymatic activity (data
not shown), and favoured assay conditions allowing 50% of
2-arachidonoyl glycerol converted into glycerol in membrane fractions
from control brains. JZL184 (5mM) (Long et al., 2009) or URB602
(1 mM) (King et al., 2007) served to determine the specific contribu-
tion of monoacylglycerol lipase to 2-arachidonoyl glycerol degradation.
URB597 (20 nM) (Mor et al., 2004) was used to test the changes in
anandamide-degrading activity in Alzheimer’s disease brains. Enzyme
activity was expressed as picomole [1,2,3-3H]glycerol formed/mg pro-
tein/15 min and picomole [3H]ethanolamine formed/mg protein/
15 min, respectively. Human amyloid-b1-40 (PolyPeptides) were diluted
and used as described for amyloid-b1–42 (Supplementary Methods).
Methods to assess transient receptor potential cation channal sub-
family V member 1 (TRPV1) channel binding in post-mortem hippo-
campal samples are provided in the online Supplementary Material.
Statistical analysis
Data were analysed using Statistical Package for the Social Sciences
17.0 (SPSS Inc.). Integrated optical density of immunoreactive targets
in Western blot experiments, and decay constants from electrophysi-
ology measurements were evaluated using Student’s t-test (on inde-
pendent samples). Linear regression analysis of CB1 cannabinoid receptor,
DAGLs and monoacylglycerol lipase isoforms, synaptic markers, disease
stages and/or post-mortem delay (Supplementary Fig. 4) was performed
by defining Pearson’s correlation coefficient. Data were expressed as
mean  SEM. P5 0.05 was considered statistically significant.
Results
Here, we focus on molecular rearrangements of 2-arachidonoyl
glycerol signalling networks progressively affecting synaptic neuro-
transmission during Alzheimer’s disease in human brain and ex-
perimental models of amyloid-b synaptotoxicity. We also present
data on N-acyl phosphatidylethanolamide-specific phospholipase
D (NAPE-PLD), fatty-acid amide hydrolase (FAAH) and TRPV1,
significantly extending available knowledge on Alzheimer’s-related
modifications to anandamide signalling (Benito et al., 2003;
Ramirez et al., 2005) in Supplementary Fig. 5. Changes of CB2
cannabinoid receptor expression in this cohort of subjects with
Alzheimer’s disease have recently been reported elsewhere
(Halleskog et al., 2011).
CB1 cannabinoid receptor expression
is unchanged in Alzheimer’s disease
Cellular mapping studies, combined with ultrastructural analysis,
unequivocally position CB1 cannabinoid receptors presynaptically
in both excitatory and inhibitory nerve endings of rodent (Katona
et al., 2006), primate (Harkany et al., 2005) and human hippo-
campus (Ludanyi et al., 2011). However, the impact of ageing or
Alzheimer pathology on CB1 cannabinoid receptor expression and
(sub-)cellular distribution in the human hippocampus remain am-
biguous (Westlake et al., 1994; Lee et al., 2010).
We have studied clinicopathologically-verified patient material con-
sisting of 10 subjects classified as controls (4 Braak I stage) aged 52–
96 years, nine subjects presenting Braak stage III/IV pathology and
aged 72–105 years, as well as nine patients with pathological in-
dices of Braak stage VI and aged 69–90 years (Supplementary
Table 1). Braak stage III/IV and Braak stage VI patients had sig-
nificantly increased amyloid-b levels (Supplementary Fig. 1A) and
synaptic modifications as suggested by decreased levels of
synaptosomal-associated protein of 25 kDa (SNAP25) (Garbelli
et al., 2008) and postsynaptic density protein of 95 kDa (PSD95)
(Sampedro et al., 1982), pre- and postsynaptic markers, respect-
ively (Supplementary Fig. 1C and D).
Western analysis demonstrated CB1 cannabinoid receptor ex-
pression in the aged human hippocampus (Fig. 1A). CB1 canna-
binoid receptors were of 52 kDa molecular weight suggesting that
mature, non-truncated receptors were detected in post-mortem
brain homogenates (Fig. 1A and B). CB1 cannabinoid receptor
levels remained unchanged in patients with Braak stage III/IV or
Braak stage VI pathology (Fig. 1B). We performed correlation ana-
lysis between SNAP25, PSD95 and CB1 cannabinoid receptors to
test whether individual variations in CB1 cannabinoid receptor
levels may be related to those of SNAP25 or PSD95 at excitatory
synapses. However, CB1 cannabinoid receptor expression did not
correlate with that of either SNAP25 (Supplementary Fig. 1E) or
PSD95 (data not shown).
Immunohistochemistry revealed a dense meshwork of CB1 can-
nabinoid receptor + axons with CB1 cannabinoid receptors particu-
larly enriched in presynapses that contained synaptophysin, a
pan-presynaptic marker (Schubert et al., 1991), in the strata pyr-
amidale and radiatum of the Ammon’s horn 1–3 subfields (Fig. 2A
and B; Supplementary Fig. 6A–A3), and the stratum moleculare of
the fascia dentata (Supplementary Fig. 7A) of aged human sub-
jects. High-resolution laser-scanning microscopy confirmed that
CB1 cannabinoid receptors localized to synaptophysin
+ presy-
napses targeting either the perisomatic segment (Fig. 2C–C3) or
distal dendrites (Fig. 2D–D3) of pyramidal neurons. Accordingly,
CB1 cannabinoid receptor
+/microtubule-associated protein 2 +
(MAP2 +) double-labelled structures were not observed (MAP2 is
a ubiquitous somatodendritic marker of neurons) (Peng et al.,
1986). CB1 cannabinoid receptor distribution in Braak stage III/
IV/Braak stage VI cases was unaltered; CB1 cannabinoid receptor
+
axons coursed in both soma-rich laminae, including the stratum
granulosum (Fig. 2E) and receptive fields (e.g. stratum moleculare;
Fig. 2E). Notably, CB1 cannabinoid receptor
+ axons appeared to
engulf senile plaques (Fig. 2E1–E3) with CB1 cannabinoid recep-
tor + bouton-like varicosities commonly situated within the
amyloid-b-dense plaque cores. Therefore, we conclude that CB1
cannabinoid receptor expression and axonal distribution remain
largely unaffected in Alzheimer’s disease.
DAGLb but not DAGLa redistribution in
Alzheimer’s disease
The long-held view of 2-arachidonoyl glycerol biosynthesis posits
DAGLs as Ca2 + -regulated enzymes synthesizing this endocanna-
binoid (Bisogno et al., 2003). DAGLs reside in the perisynaptic
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annulus, a proximal zone surrounding the postsynaptic density at
CB1 cannabinoid receptor
+ excitatory synapses (Uchigashima
et al., 2007), also in human brain (Ludanyi et al., 2011).
Epilepsy-induced sclerotic neurodegeneration in human brain re-
duces DAGLa but not DAGLb expression by 60% suggesting
that impaired 2-arachidonoyl glycerol synthesis may occur under
disease conditions (Ludanyi et al., 2008).
We have tested this possibility by analysing DAGLa and DAGLb
protein expression in Braak stage III/IV, Braak stage VI and
age-matched control brains (Fig. 1A, C and C1). We found a
gradual increase in the protein levels of both enzymes, paralleling
Alzheimer’s progression [DAGLa: 145.4  50.9% of control, n = 7
(Braak stage III/IV), 193.9  41.9% of control, n = 6, P = 0.076
versus control (Braak stage VI); DAGLb: 155.1  29.1% of control
n = 7 (Braak stage III/IV); 175.9  23.7% of control n = 6,
P = 0.015 versus control (Braak stage VI); Fig. 1C and C1]. Next,
we explored whether DAGLa expression correlates with that of
DAGLb. Analysis of discrete subject cohorts revealed the lack of
an expressional relationship between the two enzymes in control
or Braak stage III/IV brains (Fig. 1D). In contrast, we found a
strong inverse relationship between DAGLa and DAGLb protein
levels in Braak stage VI brains (Fig. 1D). These findings suggest
that either DAGLa is replaced by DAGLb postsynaptically or
DAGLa and DAGLb segregate to distinct cell types with independ-
ent expressional control for DAGLs in Alzheimer’s disease.
Multiple immunofluorescence histochemistry using affinity-pure
antibodies (Supplementary Fig. 2), and appropriate histochemical
(Supplementary Fig. 3) and imaging (Supplementary Fig. 6B) con-
trols, in the Ammon’s horn 1–3 subfields of the aged human
hippocampus and fascia dentata (Fig. 3A and Supplementary
Fig. 7B–B2) revealed DAGLa
+ and DAGLb+ puncta along the den-
dritic trees of pyramidal neurons (Fig. 3B–B2) and granule cells
(Supplementary Fig. 7B–B2). The density of DAGLa
+ puncta ex-
ceeded that of DAGLb+ structures (Fig. 3B–B2, C1–C3 and E1).
High-resolution microscopy along individual MAP2 + dendrite seg-
ments showed frequent DAGLa/DAGLb co-localization (Fig. 3C–C3).
Three dimensional reconstruction of select dendrites upon capturing
consecutive images in orthogonal stacks verified that both DAGLa
and DAGLb were localized within dendritic compartments and accu-
mulated at the stem of dendritic spines (Fig. 3D and D1).
Figure 1 Changes in DAGL and monoacylglycerol lipase protein expression in human hippocampus coincide with Alzheimer’s progres-
sion. (A) Representative images of molecular targets resolved by western blotting. Data (in kiloDaltons) indicate the calculated molecular
weights of the molecules of interest. Solid and open arrowheads identify monoacylglycerol lipase’s 33 kDa and 30 kDa isoforms,
respectively. Calculated molecular weights corresponded with those measured in particular experiments in all cases. We did not observe
modifications to the molecular weights of any of the targets analysed (otherwise represented as vertical size shifts) when comparing data
from control, and cohorts with moderate or severe Alzheimer’s disease [Braak stage III/IV (B2–4) and Braak stage VI (B6), respectively].
Normalized expression (average of controls = 1.0) of CB1 cannabinoid receptors (CB1R) (B), DAGLa (C;
+P5 0.1), DAGLb (C1), ABHD6
(E), 30 kDa (F) and 33 kDa (F1) isoforms of monoacylglycerol lipase. Individual data points and their colour coding correspond to
post-mortem cases listed in Supplementary Table 1. b-actin was used as loading control to normalize our data (Supplementary Fig. 1B and
B1). Horizontal lines represent the mean value of particular patient cohorts. (D) DAGLa and DAGLb levels correlated positively in controls
(not marked), lost correlation in Braak stage III/IV, while exhibited a strong negative expressional relationship in Braak stage VI
(red dashed line). (G) Monoacylglycerol lipase isoform expression positively correlates during Alzheimer’s progression. *P50.05
(Student’s t-test). 2-AG = 2-arachidonoyl glycerol.
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Quantitative morphometry showed that the Pearson’s correlation
coefficient of dual-labelled structures only marginally differs from
0, suggesting limited (if any) correlation (co-regulation) between
signal intensities for DAGLa and DAGLb (Fig. 3E). We quantita-
tively verified a higher density of DAGLa than DAGLb along
apical dendrite profiles of pyramidal cells in the Ammon’s horn
1 subfield stratum radiatum (Fig. 3E1 and see Fig. 3B–B2). Here,
24.0  3.9% of DAGLa+ postsynaptic (MAP2 + ) puncta contained
DAGLb (Fig. 3E2). In contrast, 47.7  3.1% of DAGLb+ structures
were dual labelled, suggesting that DAGLa can drive DAGLb re-
cruitment to sites of co-localization.
The distribution of DAGLa immunoreactivity remained largely
unchanged in Alzheimer’s disease, including around senile plaques
where DAGLa immunoreactivity has been found scattered in
amyloid-b-laden territories (Fig. 3F). In contrast, DAGLb immuno-
reactivity accumulated in small-diameter cell-like structures
Figure 2 CB1 cannabinoid receptor distribution in aged human hippocampus and in Alzheimer’s disease. (A) Schema of the human
hippocampal formation. Open rectangles identify the general location of images in B and E. (B) CB1 cannabinoid receptor (CB1R)
immunoreactivity overlaps with synaptophysin + nerve terminals targeting the perisomatic region (C) as well as apical dendrites (D)
of Ammon’s horn 1 pyramidal neurons. High-resolution microscopy reveals CB1 cannabinoid receptor
+/synaptophysin + terminals
(arrowheads) around pyramidal cell perikarya (C–C3) and dendrites (D–D3). Note the mutually exclusive localization of CB1 cannabinoid
receptors and MAP2 + dendrites. Dashed lines encircle neuronal somata (C) and dendrite (D). Asterisks in C are overlain on neuronal
nuclei. (E) CB1 cannabinoid receptor
+ afferents engulf cells in the granular layer abundantly immunoreactive for amyloid-b17-24
[Ab(17–24)], likely localizing intracellular amyloid precursor protein, as well as amyloid-b17–24
+ senile plaque (open rectangle). (E1–E3) The
density of CB1 cannabinoid receptor
+ axons and synapses appear unchanged in the proximity of senile plaques. Instead, CB1 cannabinoid
receptor + processes appear to accumulate locally around, and even penetrate senile plaques (arrows). CA = Ammon’s horn; DF = dentate
fascia; sub = subiculum. Scale bars = 20 mm (B, E and E3), 12 mm (C3), 4mm (D3).
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associated with senile plaques and apposing CB1 cannabinoid re-
ceptor + axons (Fig. 3F1 and F2). By using ionized Ca
2 + -binding
adaptor molecule-1 (IBA-1) we demonstrate that activated micro-
glia (Xu et al., 2008) frequently surrounding senile plaques express
DAGLb in Braak stage VI brains (Fig. 3G–G2). Together, these
findings suggest that both DAGLs can coexist in dendritic
spines of hippocampal neurons in the aged human hippocampus.
In addition, microglia represent a novel cellular component
Figure 3 Differential DAGLa and DAGLb expression and localization in aged human hippocampus and in Alzheimer’s disease.
(A) Schematic overview of hippocampal subfields with open rectangles identifying the localization of dendritic fields shown in B and F.
(B) MAP2 + dendritic shafts (arrows) are embedded in a fine meshwork of DAGLa+ and/or DAGLb+ puncta, with the density of DAGLa
immunoreactivity surpassing that of DAGLb in the aged human hippocampus (control). (C) High-resolution imaging reveals coexistence of
DAGLa and DAGLb (arrowheads) in MAP2 + compartments. (D) 3D reconstruction of a MAP2 + pyramidal dendrite verifies the post-
synaptic recruitment of DAGLs, and high-power rendering positions both DAGLa and DAGLb in the dendritic spine neck (D1).
(E) Pearson’s correlation coefficient suggests moderate positive correlation between the fluorescence maxima of DAGLa and DAGLb.
(E1 and E2) Area occupancy and co-localization coefficients for DAGLa and DAGLb immunoreactivities verify the greater abundance
of DAGLa, and reveal differences in their probability of co-localization, respectively. Data were expressed as means  SEM. (F) The
distribution of DAGLa (arrowheads) does not change around amyloid-b17-24
+ senile plaques. However, DAGLb immunoreactivity focally
concentrates in periplaque regions (F1) in small-diameter cell-like structures (arrowheads, F1) but not CB1 cannabinoid receptor
+ (CB1R)
processes (open arrows). Such DAGLb+ cells closely appose (arrowheads, F2) CB1 cannabinoid receptor
+ axon terminals (arrows, F2), and,
based on their IBA-1 expression, were identified as activated microglia in Alzheimer’s brains (arrows, G–G2). Asterisks in G–G2 pinpoint the
soma of the microglial cell. CA = Ammon’s horn; DF = dentate fascia; sub = subiculum. Scale bars = 40mm (B2), 10 mm (F and F1), 4mm
(C3, F2 and G3).
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participating in 2-arachidonoyl glycerol biosynthesis in Alzheimer’s
disease. The specific accumulation of DAGLb+ microglia around
senile plaques could lead to the focal enhancement of
2-arachidonoyl glycerol signalling, affecting neuronal excitability
(Busche et al., 2008), unless compensated by molecular rearrange-
ments in 2-arachidonoyl glycerol-degrading enzymatic capacity in
Alzheimer’s brains.
ABHD6 expression in Alzheimer’s
disease
ABHD6 is a recently characterized serine hydrolase degrading
2-arachidonoyl glycerol in the nervous system (Marrs et al.,
2010). While activity-based protein profiling identified ABHD6 as
a candidate to hydrolyse 2-arachidonoyl glycerol in microglia-like
cells, follow-up histochemical studies in rodent brain identified the
somatodendritic domain of neurons as major, postsynaptic foci
accumulating ABHD6 (Marrs et al., 2010). Western blotting
demonstrated that ABHD6 protein is present in the aged human
hippocampus (Fig. 1A and E). Comparative analysis revealed un-
changed ABHD6 levels across Braak stage III/IV, Braak stage VI
and age-matched control tissues (Fig. 1A and E). However, these
findings do not exclude the possibility that neuronal and glial
ABHD6 expression differentially contribute to total ABHD6 levels
in control versus Alzheimer’s brains.
We show, by using affinity-pure anti-ABHD6 antibodies (Marrs
et al., 2010), ABHD6-like immunoreactivity decorating the somatic
membrane and apical dendrites of pyramidal cells in the hippo-
campus of aged humans (Fig. 4A–A2). We found Alzheimer’s
progression associated with a gradual decrease of ABHD6-like
immunoreactivity in hippocampal neurons (Fig. 4B and B1).
Notably, the distribution of ABHD6 and AT8, the latter identifying
tau hyperphosphorylated at Ser202/Thr205 residues in degenerat-
ing neurons (Goedert et al., 1989), is mutually exclusive in Braak
stage VI brain, suggesting that Alzheimer-related cytoskeletal
damage can arrest ABHD6 expression (Fig. 4C and C1). In con-
trast, ABHD6 + small diameter, multipolar cells lacking MAP2 ac-
cumulate in Alzheimer’s brains (Fig. 4B and B1). We demonstrated
that microglia can express ABHD6 (particularly in Braak stage VI)
by revealing an intricate network of ABHD6 + /IBA-1 + but MAP2-
microglia end-feet scattered around hippocampal neurons
(Fig. 4B1 and B2). In addition, we found that amyloid-b-containing
neuritic plaques attract ABHD6 +/IBA-1 + microglia, which accu-
mulate both around and within senile plaques (Fig. 4D–D3). In
summary, our data uncover a postsynaptic expression site for
ABHD6 in neurons of the aged human hippocampus, as well as
widespread ABHD6 expression by activated microglia in
Alzheimer’s disease.
Monoacylglycerol lipase is recruited
to presynapses and astroglia in aged
human brain
Although monoacylglycerol lipase has many substrates (Nomura
et al., 2010), it is considered to be the major enzyme
inactivating480% of 2-arachidonoyl glycerol in adult rodent
brain (Blankman et al., 2007). Chronic CB1 cannabinoid receptor
desensitization due to increased 2-arachidonoyl glycerol, but not
other bioactive lipid levels in monoacylglycerol lipase/ mice,
confirms that 2-arachidonoyl glycerol is primarily degraded by
monoacylglycerol lipase in the nervous system (Schlosburg et al.,
2010). Monoacylglycerol lipase is localized to presynapses in
rodent (Dinh et al., 2002) and human brains (Ludanyi et al.,
2011). However, monoacylglycerol lipase expression and subcellu-
lar localization remain elusive during ageing and in Alzheimer’s
disease.
We found, by using two antibodies directed against non-
overlapping monoacylglycerol lipase epitopes and validated in
monoacylglycerol lipase/ mice (Keimpema et al., 2010;
Supplementary Fig. 2), prominent monoacylglycerol lipase immu-
noreactivity at three sites in the aged human hippocampus: (i) the
somatic region of dentate granule cells (Fig. 5A–B1) and CA1 pyr-
amidal neurons (Fig. 5C); (ii) nerve endings concentrating in the
stratum moleculare of the dentate fascia (Fig. 5B1) and the stra-
tum radiatum of the Ammon’s horn subfields (Fig. 5C); and (iii)
astroglia-like cells randomly distributed across hippocampal lami-
nae (Fig. 5B1 and H). Somatic monoacylglycerol lipase immunor-
eactivity in pyramidal cells is primarily present in the cytosol
(Fig. 5D–D3). Although moderate monoacylglycerol lipase immu-
noreactivity was occasionally seen in the proximal segment of
apical dendrites, overall monoacylglycerol lipase is absent in the
dendritic tree of principal neurons (Fig. 5C). Monoacylglycerol
lipase ubiquitously coexists with CB1 cannabinoid receptors in
presynapse-like puncta apposing pyramidal cells’ dendrites, sug-
gesting that monoacylglycerol lipase retains its presynaptic local-
ization in the aged human hippocampus (Fig. 5E–E3). We have
confirmed our histochemical findings by 3D reconstruction of pyr-
amidal cell dendrites and perisynaptic astroglia end-feet (Fig. 5F
and F1) and found a complete lack of co-localization between
monoacylglycerol lipase and MAP2, a somatodendritic marker of
neurons (Peng et al., 1986), as well as glial fibrillary acidic protein
in astroglia.
Next, we asked whether monoacylglycerol lipase and CB1 canna-
binoid receptors coexist throughout the hippocampal parenchyma or
are only recruited to synaptic terminal-like specializations apposing
MAP2+ somatodendritic elements. Quantitative immunofluorescence
morphometry (Supplementary Fig. 6C) revealed moderate correl-
ation between the intensities of monoacylglycerol lipase and CB1
cannabinoid receptor immunoreactivities at sites of co-localization
(Fig. 5G), suggesting that recruitment of the two markers to the
same sites may proceed largely independently of one another. We
found that the area occupancy of monoacylglycerol lipase immu-
noreactivity exceeds that of the CB1 cannabinoid receptor
(Fig. 5G1) implying differences between the axonal transport,
overall expression levels or subcellular recruitment of monoacylgly-
cerol lipase and CB1 cannabinoid receptor in the aged human
brain. Accordingly, we found that only 12.6  1.2% of monoacylgly-
cerol lipase+ structures are labelled for CB1 cannabinoid receptors. In
contrast, 25.1  2.2% of CB1 cannabinoid receptor immunoreactivity
co-localizes with that of monoacylglycerol lipase (Fig. 5G2). Thus, our
data suggest that monoacylglycerol lipase can accumulate in CB1
cannabinoid receptor+ presynapses in the human hippocampus to
terminate retrograde 2-arachidonoyl glycerol signalling.
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We used western analysis to compare monoacylglycerol lipase
protein levels in Braak stage III/IV and Braak stage VI patients as
well as age-matched controls, and found significantly increased
levels of both major monoacylglycerol lipase isoforms in Braak
stage VI hippocampi (Fig. 1A, F and F1). Correlation analysis sub-
stantiated a positive relationship between expression levels of the
two major monoacylglycerol lipase isoforms (Fig. 1G). We have
refined these results by verifying that advancing Braak stages in
Alzheimer’s disease couple to gradually increased monoacylgly-
cerol lipase levels in an isoform (Fig. 6A and A1) and post-mortem
delay-independent manner (Fig. 6A2). Since we performed west-
ern analysis on total protein samples from human hippocampi,
several unanswered questions remained including: (i) whether
increased monoacylglycerol lipase concentrations represent novel
expression sites as a result of ongoing neurodegeneration as well
as neuroinflammation in Alzheimer’s disease; (ii) whether defunct
Figure 4 Pathological alterations in the cellular distribution of serine hydrolase ABHD6 in Alzheimer’s hippocampus. (A–A2) ABHD6 is
distributed along the somatodendritic axis of hippocampal pyramidal cells in aged (control) human hippocampus. (B) We found ABHD6
expression in small, multipolar MAP2 cells, presumed microglia, coincident with a decrease in dendrite labelling in neurons (asterisk) in
Braak 2–4 disease. (B1 and B2) This Alzheimer-related ABHD6 distribution pattern is exacerbated in Braak 6 with ABHD6 immunoreactivity
localized to small calibre, IBA1 + microglia processes. (C and C1) ABHD6 is excluded from AT8
+ neurons (asterisk), though retained in
proximal dendrites of cells without appreciable neurofibrillary pathology. (D–D3) ABHD6
+ /IBA1 + microglia populate plaque-laden regions
in severe Alzheimer’s disease. Open and solid arrowheads point throughout to ABHD6 + dendrites and microglia-like cells, respectively.
Scale bars = 12 mm.
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Figure 5 Monoacylglycerol lipase in the aged human hippocampus. (A) Schematic overview of the human hippocampal formation with
open rectangles identifying the surface areas presented in panels B, C and H. (B and B1) Monoacylglycerol lipase immunoreactivity
(open arrowheads) is confined not only to the somata of granule cells but also to ramifying astroglia-like cells in the dentate gyrus
(open arrowheads). (C) CB1 cannabinoid receptor
+ afferents target monoacylglycerol lipase + Ammon’s horn 1 subfield pyramidal cells.
Open rectangles point out the location of insets in D and E. (D–D3) Monoacylglycerol lipase decorates the cytoplasm of pyramidal cells.
(E–E3) Monoacylglycerol lipase accumulates in presynapses as revealed by the presence of monoacylglycerol lipase
+/CB1 cannabinoid
receptors + terminals on pyramidal cell dendrites (arrows). Dashed lines encircle neuronal somata (D) and dendrite (E). (F and F1) 3D
reconstruction of a dendrite segment confirms that monoacylglycerol lipase (open arrowheads) is excluded from dendrites/dendritic
spines, as well as astroglial end-feet. (G) Pearson’s correlation coefficient of monoacylglycerol lipase and CB1 cannabinoid receptor
fluorescence intensities. (G1) Relative area coverage of monoacylglycerol lipase
+ and CB1 cannabinoid receptor
+ structures over
pyramidal cell dendrites in the stratum radiatum. (G2) Co-localization coefficients for monoacylglycerol lipase and CB1 cannabinoid
receptor immunoreactivities reveal differential probabilities for these molecular targets to coexist. (H) Monoacylglycerol lipase accumulates
on the membrane surface of a subset of glial fibrillary acidic protein (GFAP) + astroglia in aged human brain. Scale bars = 80 mm (B1),
20 mm (C and H), 6 mm (D3 and E3).
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neurons presenting cytoskeletal abnormalities, such as hyperpho-
sphorylated tau, lose monoacylglycerol lipase expression as seen
for ABHD6; and (iii) whether Alzheimer’s disease impacts the
metabolic competence of monoacylglycerol lipase by impairing
its recruitment to the plasmalemma.
In the Alzheimer’s hippocampus, we find that monoacylglycerol
lipase + /IBA-1 + microglia cells accumulate around senile plaques
(Fig. 6B and B1). Although quantitative morphometry was not an
objective of the present report, a clear increase in the density of
monoacylglycerol lipase + microglia can be seen when comparing
Braak stage III/IV versus Braak stage VI brains. Hippocampal prin-
cipal cells—both pyramidal cells of the Ammon’s horn subfields
and dentate granule cells—express monoacylglycerol lipase. We
found that AT8 + pyramidal cells retain monoacylglycerol lipase
expression (Fig. 6C–C2’), although at significantly lower levels
than those without intracellular tau pathology [Fig. 6D;
121.85  3.73 grey scale unit (AT8- neurons) versus 81.75 
8.31 grey scale unit (AT8+ neurons); P50.001]. Our data
cumulatively indicate that both microglia (Fig. 6B) and astroglia
(Fig. 5H) can serve as sources of monoacylglycerol lipase, and a
progressive shift of monoacylglycerol lipase expression from
damaged neurons to activated micro- and astroglia occurs in
Alzheimer’s disease.
Gene expression profiling in mouse
microglia
Activated microglia have previously been shown to express CB2
cannabinoid receptors in Alzheimer’s disease (Benito et al., 2003;
Ramirez et al., 2005) and Down’s syndrome (Nunez et al., 2008),
and pharmacological challenges can increase 2-arachidonoyl gly-
cerol production in this cell type (Walter et al., 2003). However,
coexistence of molecular components determining an operational
2-arachidonoyl glycerol signalling network in activated microglia
(i.e. CB/CB2 cannabinoid receptors, DAGLs, ABHD6 and
Figure 6 Monoacylglycerol lipase localization in Alzheimer hippocampus. (A and A1) Monoacylglycerol lipase (MGL) isoform
expression exhibits positive correlation with Alzheimer’s progression. (A2) This relationship is not biased by the post-mortem
delay (h). (B and B1) IBA-1
+ microglia cells (arrowheads) recruited to senile amyloid plaques express monoacylglycerol lipase.
(C–C2) Monoacylglycerol lipase expression is retained at reduced levels in neurons with moderate (C and double asterisk) and severe
(C1, C2 and single asterisk) neurofibrillary pathology. (D) Quantitative immunofluorescence analysis of monoacylglycerol lipase levels in
neurons with (AT8 +) or without (AT8 +) hyperphosphorylated tau. Symbols in brackets denote group means. g.s.u. = grey-scale unit.
***P50.001 (Student’s t-test). Scale bars = 12 mm (C’–C2’), 8mm (B and B1).
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monoacylglycerol lipase) capable to sustain autocrine and/or
paracrine 2-arachidonoyl glycerol signalling remains unknown.
We performed Affymetrix gene expression profiling coupled to
quantitative polymerase chain reaction analysis (Fig. 7A) to test
the expression of CB1 cannabinoid receptors, CB2 cannabinoid
receptors, as well as 2-arachidonoyl glycerol metabolic enzymes
in primary mouse microglia under experimental conditions
mimicking pro-inflammatory transformation in Alzheimer’s brains
(Halleskog et al., 2011). Under control conditions, CB1 cannabinoid
receptor, CB2 cannabinoid receptor, DAGLa, DAGLb, monoacylgly-
cerol lipase, ABHD6 and ABHD12 expression levels exceeded the
detection minimum of Affymetrix chips (data not shown). Microglia
activation can proceed through amyloid-b-independent mechanisms
in vivo (Halleskog et al., 2011). Therefore, we applied WNT-3A
(300 ng/ml) to induce pro-inflammatory transformation of primary
mouse microglia. WNT-3A significantly increased messenger RNA
transcript levels of interleukin 6 and tumour necrosis factor a,
pro-inflammatory cytokines, relative to controls (Halleskog et al.,
2011). Simultaneously, WNT-3A reduced CB2 cannabinoid recep-
tor, DAGLa and DAGLb messenger RNA expression, while leaving
CB1 cannabinoid receptor, monoacylglycerol lipase and ABHD6/12
expression unchanged (Fig. 7A). Quantitative polymerase chain re-
action analysis of N13 microglia-like cells exposed to fibrillar
amyloid-b1–40 (100 nM versus non-treated controls), known to ac-
tivate microglia (Ramirez et al., 2005), showed significantly
decreased messenger RNA transcript levels of CB1 cannabinoid
receptors (61.3  3.1% of control; n = 4/condition; P = 0.017)
and DAGLa (35.2  6.1% of control; n = 3–4/condition;
P = 0.042) but not of other molecular components of
2-arachidonoyl glycerol signalling (CB2 cannabinoid receptor:
11.6  16.7%, P40.1, n = 4/condition; monoacylglycerol
lipase: 60.3  4.4%; P40.1, n = 3/condition; Fig. 7A). In
sum, these data demonstrate that microglia can express receptor
and enzyme components of 2-arachidonoyl glycerol signalling net-
works, and respond to pro-inflammatory stimuli by transcriptional
regulation of rate-limiting molecular constituents of 2-arachidonoyl
glycerol signalling.
2-Arachidonoyl glycerol hydrolysing
activity in Alzheimer’s disease and on
exposure to amyloid-b
Rearrangements in 2-arachidonoyl glycerol signalling networks
may ultimately amplify Alzheimer-related synaptic impairment if
subcellular enzyme redistribution is associated with impaired en-
zymatic activity. Acute amyloid-b infusion in the rodent hippocam-
pus increases 2-arachidonoyl glycerol concentrations, a finding
that has been interpreted as an endogenous neuroprotective
mechanism against amyloid-b-induced oxidative stress (van der
Stelt et al., 2006). Here, we have tested the alternative hypothesis
that amyloid-b-induced increase in 2-arachidonoyl glycerol levels
reflects impaired 2-arachidonoyl glycerol catabolism under disease
conditions. We have focused on monoacylglycerol lipase as a can-
didate whose recruitment from the cytosol to its metabolically fa-
voured position in the internal leaflet of the plasmalemma (Labar
et al., 2010) may be impeded by amyloid-b-induced oxidative
damage to biological membranes in Alzheimer’s disease (Ramirez
et al., 2005; Querfurth and LaFerla, 2010).
We measured the rate of 2-arachidonoyl glycerol degradation in
frontal cortices of patients with Alzheimer’s disease and age-
matched controls by determining the amount of [1,2,3-3H]glycerol
after incubating membrane or cytosol fractions with [3H]2-
arachidonoyl glycerol. Membrane-associated 2-arachidonoyl gly-
cerol hydrolysis significantly decreased in subjects with
Alzheimer’s disease, as compared with controls (28% of control,
P50.05; Fig. 7B). In turn, 2-arachidonoyl glycerol-degrading cap-
acity in the cytosol increased proportionally in Alzheimer’s brains
(65% of control, P5 0.05; Fig. 7B), suggesting the subcellular
redistribution of 2-arachidonoyl glycerol-degrading enzymes in
human brain [total activity: 2468  96 (control) versus
2391  122 (Alzheimer) picomole 2-arachidonoyl glycerol-
degraded/mg protein/15 min; P = 0.635, n = 9/group]. Multiple
enzymes, including monoacylglycerol lipase, ABHD6 and FAAH,
contribute to 2-arachidonoyl glycerol degradation in the adult
brain (Blankman et al., 2007). To assess monoacylglycerol lipase’s
specific role in altered 2-arachidonoyl glycerol hydrolysis in
Alzheimer’s disease, we measured the rate of [3H]2-arachidonoyl
glycerol degradation in the presence of the monoacylglycerol lipase
inhibitors, JZL184 (5 mM; Fig. 7C and C1) (Long et al., 2009) or
URB602 (1 mM; Supplementary Fig. 9) (King et al., 2007). We
found that JZL184 inhibits 50.2% of 2-arachidonoyl glycerol hy-
drolysis in membranes prepared from control brains (P5 0.01;
Fig. 7C). In contrast, JZL184 inhibits only 29.6% (P50.05) of
cytosolic 2-arachidonoyl glycerol hydrolysis in control human-
cortical homogenates (Fig. 7C1). In membrane preparations from
Alzheimer’s brains (Fig. 7C), 11.6% of 2-arachidonoyl glycerol
hydrolysis activity is eliminated by JZL184, coincident with a sig-
nificant reduction of membrane-associated monoacylglycerol lipase
protein levels in the cerebral cortex of subjects with Alzheimer’s
disease (Supplementary Fig. 8A–A2). Conversely, surplus
2-arachidonoyl glycerol hydrolysis activity in cytosol fractions of
Alzheimer’s brains is JZL184 sensitive (32.0%; P50.01 versus
vehicle-treated controls; Fig. 7C1). URB602 exhibited a similar
pharmacological profile (Supplementary Fig. 8B and B1). We
excluded the contribution of FAAH to 2-arachidonoyl glycerol deg-
radation by showing negligible (410%) inhibition by URB597, a
potent FAAH inhibitor (Mor et al., 2004) (see also Supplementary
Fig. 8C). These data suggest that (i) monoacylglycerol lipase
selectively undergoes subcellular redistribution; (ii) the contri-
bution of JZL184/URB602-insensitive enzymes to 2-arachidonoyl
glycerol degradation (e.g. ABHD6 in microglia, Fig. 4B1) increases
in Alzheimer’s disease; and (iii) FAAH—whose activity is
decreased in Alzheimer’s disease (Supplementary Fig. 8C)—does
not contribute focally to 2-arachidonoyl glycerol hydrolysis in
human brain.
Next, we hypothesized that amyloid-b may impact the activity
of enzymes involved in 2-arachidonoyl glycerol hydrolysis.
Therefore, membrane and cytosol fractions from control brains
were acutely exposed to amyloid-b1–40 at 1mM final concentra-
tion. Pre-incubation with amyloid-b1–40 for 10 min increased
2-arachidonoyl glycerol catabolism in both membrane and cytosol
fractions of human cortices [membrane: 2118  73 (control;
n = 9) versus 2398  109 (amyloid-b1–40; n = 8), P = 0.045;
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Figure 7 2-Arachidonoyl glycerol degradation in Alzheimer’s disease and its amyloid-b1-40-induced activation. (A) Pro-inflammatory
transformation by WNT-3A (300 ng/ml, 6 h) (Halleskog et al., 2011) down-regulates monoacylglycerol lipase (MGL) expression in primary
mouse microglia. Interleukin-6 and tumour necrosis factor (TNF) were used as positive (internal) controls. (B) 2-Arachidonoyl glycerol
is differentially metabolized in the frontal cortex in Alzheimer’s disease: Membrane-associated 2-arachidonoyl glycerol-degrading
enzymatic activity is decreased, while cytosolic 2-arachidonoyl glycerol-degrading activity is significantly increased, relative to controls.
(C) Membrane-associated monoacylglycerol lipase activity accounts for 60% of total 2-arachidonoyl glycerol hydrolysis activity as
revealed by JZL184 application (Supplementary Fig. 8B and B1) in membrane samples prepared from control human specimens. Note that
JZL184-sensitive 2-arachidonoyl glycerol-degrading activities are selectively lost in Alzheimer’s disease. (C1) 2-Arachidonoyl glycerol
hydrolysis activity significantly increases in cytosol fractions from Alzheimer’s brains, as compared to controls. JZL184 partially reduces
2-arachidonoyl glycerol degradation in cytosolic fractions prepared from control brains and eliminates disease-associated enhancement of
2-arachidonoyl glycerol catabolism in Alzheimer’s brains (AD). (D) FAAH does not contribute to 2-arachidonoyl glycerol degradation at
either subcellular fraction as tested by URB597. (E) Pre-incubation of cortical tissue homogenates from control subjects with amyloid-b1–40
(Ab1–40) significantly increases both membrane-bound and cytosolic 2-arachidonoyl glycerol metabolism. (E1) Amyloid-b1-40 induces
2-arachidonoyl glycerol-degrading enzymatic activity in a dose-dependent manner. *P5 0.05, **P50.01 versus controls; ***P50.05,
****P50.01 versus non-treated samples. n/a = not analysed; NS = not significant; NT = non-treated; qPCR = quantitative polymerase
chain reaction.
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cytosol: 1038  41 (control; n = 9) versus 2265  112
(amyloid-b1–40; n = 9), P50.01; picomole 2-arachidonoyl
glycerol-degraded/mg protein/15 min; Fig. 7E] in a shallow
dose-dependent fashion (Fig. 7E1), thus mimicking changes in
2-arachidonoyl glycerol hydrolysing activity in Alzheimer’s brains.
We found that nM amyloid-b1–40 concentrations of likely patho-
physiological significance (Walsh et al., 2002) can augment
2-arachidonoyl glycerol degradation (Fig. 7E1). Thus, we conclude
that amyloid-b contributes to the control of 2-arachidonoyl gly-
cerol catabolism in the human brain and reduces monoacylglycerol
lipase’s 2-arachidonoyl glycerol hydrolytic capacity in membrane
fractions otherwise required to inactivate 2-arachidonoyl glycerol
during retrograde synaptic signalling.
Amyloid-b prolongs depolarization-
induced suppression of inhibition
Monoacylglycerol lipase removal from the plasma membrane
could increase the duration of signalling-competent 2-arachidonoyl
glycerol availability following its release from postsynaptic neu-
rons, and prolong depolarization-induced suppression of inhibition
(Kano et al., 2009). Consequently, enhanced 2-arachidonoyl gly-
cerol signalling could disrupt the balance between inhibitory and
excitatory neurotransmission. A causal relationship between high
focal amyloid-b concentration and errant 2-arachidonoyl glycerol
signalling may be particularly appealing to further the mechanistic
concept linking synaptic impairment to neuronal hyper excitability
(Busche et al., 2008; Minkeviciene et al., 2009) and excitotoxic
neuronal damage (Mattson and Chan, 2003).
Transgenic mouse models generating age-dependent amyloid-b
burden in the cerebral cortex and hippocampus, e.g. APdE9 mice
(Jankowsky et al., 2004), are popular to study molecular patho-
mechanisms of Alzheimer’s disease. However, biochemical protein
profiling suggests that APdE9 mice might be inappropriate to re-
capitulate molecular underpinnings of disrupted 2-arachidonoyl
glycerol signalling in Alzheimer’s disease (Supplementary Fig. 9).
Therefore, we tested whether bath-applied amyloid-b1–42 could
acutely evoke Alzheimer-related subcellular rearrangements in
the molecular architecture of 2-arachidonoyl glycerol signalling
networks. We show that non-fibrillar amyloid-b1–42—dissolved
freshly in the superfusate (Minkeviciene et al., 2009)—facilitates
CB1 cannabinoid receptor removal from the cytosol (89.87 
2.29% of control; n = 5, P = 0.002; Fig. 8A and A1) and enrich-
ment in membrane fractions (123.13  13.26% of control) pre-
pared from hippocampi of juvenile wild-type mice. Subcellular
DAGLa distribution appeared stochastic with a trend towards cyto-
solic enrichment (119.76  14.59%; n = 5/condition, P4 0.1;
membrane fraction: 77.48  11.15%; n = 5/condition, P = 0.052;
Fig. 8A and A2). Amyloid-b1–42 arrested monoacylglycerol lipase in
the cytosol (149.16  14.59% of control; n = 6/group, P = 0.003),
while leaving membrane-associated monoacylglycerol lipase un-
changed (97.95  14.60% control; P4 0.8; Fig. 8A and A3) in
1 h. We hypothesized that the amyloid-b1–42-induced enhanced
cell-surface availability of the CB1 cannabinoid receptor would
alter 2-arachidonoyl glycerol signalling. Therefore, we sought to
determine whether amyloid-b1–42 augments the 2-arachidonoyl
glycerol-mediated suppression of inhibitory neurotransmission in
the hippocampus. We studied depolarization-induced suppression
of inhibition at inhibitory synapses because amyloid-b1–42 accumu-
lation in senile plaques has been shown to impair GABA neuro-
transmission, thus provoking focal neuronal hyper excitability in a
transgenic model of Alzheimer’s disease (Busche et al., 2008).
Using whole-cell patch recording of Ammon’s horn 1 subfield
hippocampal neurons in brain slices prepared from juvenile mice,
we elicited a baseline depolarization-induced suppression of inhib-
ition by briefly depolarizing (1 s, from 80 to 0 mV) the pyramidal
cell (Fig. 8B). Depolarization-induced suppression of inhibition was
detected in all control cells, had a maximal magnitude of
25.7  3.1% when measured between 1 and 5 s after postsynap-
tic cell depolarization and normalized to the pre-depolarization
baseline (n = 9). The decay time constant () of depolarization-
induced suppression of inhibition was 9.15  1.39 (s). Bath appli-
cation of amyloid-b1–42 for 1 h did not significantly affect maximal
synaptic depression in pyramidal cells (depolarization-induced sup-
pression of inhibition magnitude: 32.9  4.4%, n = 10, P = 0.233
versus control; Fig. 8B1 and B2). Nevertheless, the magnitude of
synaptic depression on non-fibrillar amyloid-b1–42 pre-treatment
was significantly different from that in control cells from 5–15 s
post-stimulus [5 s: 32.5  5.1% (amyloid-b) versus 18.0  5.1%
(control), P = 0.039; 10 s: 27.4  4.3% (amyloid-b) versus
8.8  0.4% (control), P = 0.004; 15 s: 19.4  5.7% (amyloid-b)
versus 4.5  4.7% (control), P = 0.047]. Non-fibrillar amyloid-b1–
42 prolonged depolarization-induced suppression of inhibition, as
indicated by a significant increase in its mean decay time con-
stant [ = 43.69  11.99 (s), n = 10, P = 0.018 versus control].
We used AM251 (1 mM) to verify that depolarization-induced sup-
pression of inhibition was dependent on CB1 cannabinoid receptor
activation (Fig. 8C, Supplementary Fig. 10A and A1). AM251 com-
pletely abolished depolarization-induced suppression of inhibition
in all cases tested. Next, we sought to determine whether
the amyloid-b-induced enhancement of depolarization-induced
suppression of inhibition is exclusively due to CB1 cannabinoid
receptor activation or if amyloid-b uncovers a secondary mechan-
ism operating at hippocampal synapses otherwise sensitive to
AM251. We found that amyloid-b1–42 does not induce signifi-
cant depolarization-induced suppression of inhibition in the pres-
ence of AM251 (Fig. 8D and D1). Cumulatively, our data imply
that amyloid-b prolongs 2-arachidonoyl glycerol signalling, which
will impair GABAergic transmission, thus likely contributing to
the progressive development of synaptic failure in Alzheimer’s
disease.
Discussion
This report describes significant changes to (i) the molecular archi-
tecture; (ii) cellular identity; and (iii) function of 2-arachidonoyl
glycerol metabolism in defined patient cohorts with clinicopath-
ologically-verified Alzheimer’s disease, as well as in transgenic
mice and acute pharmacological models of Alzheimer’s-like neur-
onal dysfunction. Although we cannot entirely rule out altered
signal transduction downstream from CB1 cannabinoid receptors
(Lee et al., 2010), our biochemical and histochemical findings
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cumulatively highlight that 2-arachidonoyl glycerol signalling in
neurons is primarily impaired at the level of metabolic enzymatic
control of ligand availability in Alzheimer’s disease. We also
propose that activated microglia, accumulating in Alzheimer’s
brains and contributing to chronic neuroinflammation, have a
fundamental role in modifying 2-arachidonoyl glycerol signalling,
particularly in amyloid-b-laden brain microdomains around senile
plaques, and might impact synaptic communication.
A separate series of experiments were directed towards explor-
ing whether Alzheimer’s pathology alters the levels of NAPE-PLD
Figure 8 Amyloid-b1–42 triggers subcellular redistribution of 2-arachidonoyl glycerol signalling networks and prolongs
depolarization-induced suppression of inhibition. (A–A3) Representative images of molecular targets resolved by Western blotting.
Cytosol and membrane fractions are from the same sample to establish the impact of amyloid-b1–42 on subcellular receptor and enzyme
recruitment, as compared to controls in artificial cerebrospinal fluid (aCSF). Amyloid-b(1-42) [(Ab(1–42)] exposure significantly alters
intracellular versus cell surface concentrations of CB1 cannabinoid receptors (A1), DAGLa (A2) and monoacylglycerol lipase (A3). Data on
monoacylglycerol lipase (MGL) show cumulative changes in this enzyme’s 33 and 30 kDa isoforms. (B) Representative experiment
showing depolarization-induced suppression of inhibition induced by a step depolarization of an Ammon’s horn 1 pyramidal neuron.
(B1) Postsynaptic depolarization-induced reduction of spontaneous inhibitory postsynaptic currents (downward deflection from baseline) is
prolonged by bath-applied amyloid-b1–42 (1 mM). (B2) Summary of depolarization-induced suppression of inhibition magnitude and
kinetics measured in control (open circles; n = 10 cells) or in the presence of amyloid-b1–42 (solid circles; n = 11). AM251 (1 mM) abolishes
depolarization-induced suppression of inhibition in control (C), as well as amyloid-b1-42-superfused Ammon’s horn 1 pyramidal neurons
(D and D1). **P50.01 (Student’s t-test). Data were expressed as means  SEM.
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and FAAH, implicated in anandamide metabolism (Cravatt et al.,
1996; Ueda et al., 2005), or the function of TRPV1 receptors
(Kofalvi et al., 2007), binding anandamide but not 2-arachidonoyl
glycerol. We failed to detect Alzheimer’s-related changes in
either NAPE-PLD, FAAH, TRPV1 protein levels (Supplementary
Fig. 5A–F2) or [
3H]resiniferatoxin binding at TRPV1 receptors
(Fig. 5G2). However, interpretation of our data may be curtailed
by several factors including the relative paucity of information on
(i) the availability of essential phospholipid precursors in
Alzheimer’s disease; (ii) the relative contribution of enzymes
other than NAPE-PLD to anandamide biosynthesis (Simon and
Cravatt, 2008); and (iii) the mechanistic contribution of TRPV1
receptors to memory retention deficits (Micale et al., 2010).
Therefore, Alzheimer’s-related changes to anandamide bioavail-
ability and synaptic actions cannot be excluded.
Trans-synaptic 2-arachidonoyl glycerol
signalling in Alzheimer’s disease
Endocannabinoids and phytocannabinoids are recognized to exert
profound neuroprotection in models of peripheral nerve injury
(Yoles et al., 1996), excitotoxicity (Khaspekov et al., 2004) and
neurodegeneration (Ludanyi et al., 2008; Palazuelos et al., 2009;
Blazquez et al., 2011) through CB1 cannabinoid receptor/CB2 can-
nabinoid receptor-dependent (Palazuelos et al., 2009) or -inde-
pendent mechanisms (Lastres-Becker et al., 2005).
In microlesion models of Alzheimer’s disease, amyloid-b1–42 in-
fusion in the rat cerebral cortex significantly increases 2-arach-
idonoyl glycerol but not anandamide levels in the hippocampus
(van der Stelt et al., 2006). This amyloid-b1–42-induced elevation
of 2-arachidonoyl glycerol concentrations is further augmented by
inhibiting endocannabinoid reuptake to reverse hippocampal
neuronal damage and decrease glial activation, thus preventing
the loss of memory retention (van der Stelt et al., 2006). Our
data are significant as they corroborate and notably extend the
above observations by providing insights into specific Alzheimer’s-
associated molecular rearrangements of 2-arachidonoyl glycerol
metabolism. We suggest that both reactive astrocytes (Scuderi
et al., 2011) and microglia can participate in enhanced 2-arach-
idonoyl glycerol biosynthesis around amyloid-b-rich foci in the
Alzheimer’s brain. In contrast, 2-arachidonoyl glycerol-degrading
capacity in neurons could be substantially reduced if ABHD6 and
monoacylglycerol lipase expressions are significantly suppressed in
injured neurons with neurofibrillary pathology. Therefore, the net
contribution of 2-arachidonoyl glycerol signalling to suppress pre-
synaptic neurotransmitter release may be significantly increased. In
fact, ex vivo experiments recapitulate the above scenario of
amyloid-b-induced synaptic impairment by showing prolonged
depolarization-induced suppression of inhibition at inhibitory affer-
ents of Ammon’s horn 1 subfield pyramidal cells. Amyloid-b-
induced enhancement of depolarization-induced suppression of
inhibition is also important to reconcile previous findings that
have suggested both pre- and postsynaptic sites of action for
amyloid-b when disrupting spike timing-dependent plasticity at
cortical synapses (Shemer et al., 2006).
Postsynaptic NMDA and AMPA receptors are widely viewed as
key molecular targets of amyloid-b to disrupt synaptic plasticity
(Kamenetz et al., 2003; Snyder et al., 2005; Shemer et al., 2006).
In particular, amyloid-b-induced impairment of NMDA/AMPA recep-
tor trafficking at the postsynapse can disrupt Ca2 + signalling in
dendritic spines targeted by excitatory afferents (Snyder et al.,
2005). DAGLs accumulate at the neck of dendritic spines
(Yoshida et al., 2006) where they are anchored by homer-1 and
-2 family scaffolding proteins (Jung et al., 2007; Roloff et al.,
2010). Notably, soluble amyloid-b oligomers induce the disassem-
bly of homer-containing postsynaptic clusters (Roselli et al., 2009),
thus potentially affecting the subcellular recruitment and signalling
competence of DAGLs. These changes, together with increased
DAGL activity upon amyloid-b-induced Ca2 + overload in neu-
rons (provided that DAGLs are Ca2 +-dependent) (Bisogno et al.,
2003) and increased DAGL expression in microglia can signifi-
cantly increase 2-arachidonoyl glycerol availability in Alzheimer’s
disease.
Alzheimer’s disease has long been viewed as a disease stemming
from neuronal hypofunction. This concept has recently been chal-
lenged by demonstrating that neurons near amyloid-b-containing
plaques are focally ‘hyperactive’, while others away from plaque-
laden areas are silent (Busche et al., 2008). Neuronal hyperactivity
is suggested to be due to a relative decrease in synaptic inhibition
(Busche et al., 2008). We found that the molecular composition of
2-arachidonoyl glycerol signalling networks undergoes profound
modifications around amyloid-b-containing senile plaques in the
human hippocampus in Alzheimer’s disease. These observations
led us to hypothesize that if the efficacy of retrograde signalling
is increased in Alzheimer’s disease then it might contribute to
synapse silencing.
Our proof-of-concept neurophysiology experiments support
this notion by showing a significant increase in depolarization-
induced suppression of inhibition duration, thus suggesting that
2-arachidonoyl glycerol-mediated feedback may be a particular
mechanism through which amyloid-b could disrupt inhibitory
neurotransmission. Functionally, depolarization-induced suppres-
sion of inhibition may serve to lengthen the firing duration of
postsynaptic neurons by abating inhibitory inputs during periods
of high excitatory activity. By prolonging depolarization-induced
suppression of inhibition decay, amyloid-b may further extend
the excitatory neurons’ firing periods, thus increasing overall net-
work excitability. Previously, we have reported (Minkeviciene
et al., 2009) that amyloid-b induces neuronal hyper-excitability
by significantly depolarizing the resting membrane potential of
excitatory neurons and lowering their response threshold. This
effect is exerted without a requirement for preceding postsynaptic
activation, as in the case with depolarization-induced suppression
of inhibition. Thus, prolonging depolarization-induced suppression
of inhibition decay by reorganizing endocannabinoid signalling is a
potential mechanism by which amyloid-b can modulate neuronal
network excitability. Since inhibitory synapses are more resistant to
Alzheimer’s disease than excitatory ones (Bell et al., 2006), pro-
longed depolarization-induced suppression of inhibition may de-
stabilize hippocampal networks by shifting the net balance of
inhibition and excitation in favour of excitation. Thus, decreased
inhibitory neurotransmission will ultimately manifest in
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‘hyperactivity’ (Busche et al., 2008; Minkeviciene et al., 2009),
which may explain the increased incidence of unprovoked epileptic
seizures in patients with Alzheimer’s disease (Hauser et al., 1986).
Synaptic impairment is a central feature of Alzheimer-related
cognitive decline. It is widely accepted that amyloid-b preferen-
tially targets excitatory synapses (Lacor et al., 2004). CB1 canna-
binoid receptors are expressed by both inhibitory interneurons and
pyramidal cells with inhibitory terminals containing exceptionally
high levels of this receptor (Kawamura et al., 2006). Our finding
that CB1 cannabinoid receptor levels fail to correlate with pre-
synaptic markers suggests that the molecular changes in
2-arachidonoyl glycerol signalling networks we have identified
are unlikely to reflect the overall rate of synaptic demise in mod-
erate or severe Alzheimer’s disease. Even if amyloid-b induces
opposing—and proportional—changes in CB1 cannabinoid recep-
tor expression (that is, to increase CB1 cannabinoid receptor con-
tent in inhibitory but decrease CB1 cannabinoid receptor levels in
excitatory terminals), the neurochemical homogeneity of periso-
matic inhibitory synapses under endocannabinoid control (Kano
et al., 2009) suggests that amyloid-b can impose functional modi-
fications to endocannabinoid signalling at specific synapse popu-
lations. This concept is supported by the fact that acute amyloid-b
superfusion is unlikely to eliminate hippocampal synapses within
the brief superfusion period used when studying the decay of
depolarization-induced suppression of inhibition. Therefore, we
propose that endocannabinoid signalling is a key neuromodula-
tory homeostatic system mediating adaptive responses to neuro-
toxic insults (Bisogno and Di Marzo, 2008) and defining the
dynamics of presynaptic neurotransmitter release under disease
conditions.
2-Arachidonoyl glycerol signalling in
microglia: the good, the bad or the ugly?
Microglia are central to Alzheimer’s pathogenesis since their acti-
vation state determines whether they are beneficial by phagocy-
tosing cell debris or elicit neuronal injury by releasing
pro-inflammatory cytokines. Migrating microglia express CB2 can-
nabinoid receptors whose activation suppresses pro-inflammatory
cytokine production (Klegeris et al., 2003). Once activated, micro-
glia down-regulate CB2 cannabinoid receptors, as seen upon
WNT-3A challenge, to increase cytokine production. Microglia
continuously monitor the functional state of synapses via the dy-
namic motility of their processes. Disrupting neuron-glia commu-
nication (also including astrocyes) (Rodriguez et al., 2009) will
therefore culminate in the loss of glial homeostatic control, and
facilitate the onset of synaptic deficit. Thus, altered 2-arachidonoyl
glycerol signalling in activated microglia can have serious conse-
quences in Alzheimer’s disease, particularly since a 2-arachidonoyl
glycerol ‘overflow’ from activated microglia and astrocytes
(Scuderi et al., 2011) may be viewed as a volumetric insult indis-
criminately affecting synapse populations and assemblies of neu-
rons. Overall, pathogenic modifications to 2-arachidonoyl glycerol
metabolism in microglia can exacerbate synaptic impairment in
Alzheimer’s disease.
2-Arachidonoyl glycerol hydrolysis by
ABHD6 and monoacylglycerol lipase
in Alzheimer’s disease
ABHD6 and monoacylglycerol lipase terminate surplus
2-arachidonoyl glycerol to maintain temporally coordinated retro-
grade signalling (Dinh et al., 2002; Marrs et al., 2010).
Alzheimer’s pathology will ultimately modify 2-arachidonoyl gly-
cerol signalling if it either impacts the recruitment of ABHD6 and/
or monoacylglycerol lipase to signalling positions or compromises
their enzymatic activity. We found that AT8 + neurons cease
ABHD6 expression, suggesting impaired postsynaptic 2-arach-
idonoyl glycerol degradation when the cytoskeletal integrity of
neurons becomes compromised. The loss of ABHD6 recruitment
may be pathophysiologically significant since it could alter the bal-
ance of postsynaptic 2-arachidonoyl glycerol synthesis and deg-
radation such that 2-arachidonoyl glycerol could continuously
‘leak’ out of subsynaptic dendrites. Thus, the lack of ABHD6-
mediated ligand degradation may impair the temporal precision
of retrograde signalling.
Monoacylglycerol lipase-dependent 2-arachidonoyl glycerol
degradation requires monoacylglycerol lipase’s recruitment as a
dimer to the internal leaflet of the plasmalemma (Labar et al.,
2010). Our findings reveal that monoacylglycerol lipase’s associ-
ation to the plasmalemma is particularly hindered in brains inflicted
by Alzheimer’s. Instead, monoacylglycerol lipase is sequestered in
the cytosol, which we consider incompetent to degrade 2-arach-
idonoyl glycerol targeting transmembrane receptors and participat-
ing in retrograde signalling. We propose that diminished
association of monoacylglycerol lipase to the plasmalemma may
be due to intracellular acidosis or membrane damage through lipid
peroxidation (Querfurth and LaFerla, 2010). Nevertheless, our bio-
chemical data suggest the existence of compensatory mechanisms
since the contribution of JZL184 (URB602)-insensitive 2-arach-
idonoyl glycerol-degrading enzymes is markedly increased in
Alzheimer’s disease, compatible with our observation of increased
ABDH6 expression in microglia and/or astrocytes. We also found
that amyloid-b is central to regulating both the subcellular local-
ization and activity of monoacylglycerol lipase. The physiological
significance of this interaction may be increased intracellular
2-arachidonoyl glycerol degradation preventing receptor-
independent antioxidant actions of 2-arachidonoyl glycerol
(Bisogno and Di Marzo 2008), thus predisposing neurons to amy-
loid-b-induced oxidative damage.
Previous studies (Ramirez et al., 2005; Chen et al., 2011) dem-
onstrate that cannabinoids may rescue neurons under Alzheimer-
like conditions by suppressing pro-inflammatory microglia activity
(Ramirez et al., 2005). Our present results uncover novel mech-
anistic insights in neuronal (synaptic) 2-arachidonoyl glycerol sig-
nalling, as well as 2-arachidonoyl glycerol-mediated neuron-glia
interactions. We suggest that reduced pre- as well as postsynaptic
2-arachidonoyl glycerol degradation coincident with increased and
ectopic 2-arachidonoyl glycerol synthesis can disrupt the temporal
and spatial control of retrograde signalling, and—consequently—
aggravate synapse impairment in Alzheimer’s disease. Therefore,
endocannabinoid signalling networks may represent novel targets
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to reinstate the precision of synaptic communication under neu-
rodegenerative conditions associated with cognitive deficit.
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